Cohesiveness of Powdered Co-Amorphous Olanzapine and Impact on Tablet Production †
Abstract
:1. Introduction
2. Materials and Methods
3. Results and Discussion
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- da Costa, N.F.; Pinto, J.F.; Fernandes, A.I. Co-amorphization of olanzapine for solubility enhancement. Ann. Med. 2019, 51, 87. [Google Scholar] [CrossRef] [Green Version]
- Lenz, E.; Jensen, K.T.; Blaabjerg, L.I.; Knop, K.; Grohganz, H.; Löbmann, K.; Rades, T.; Kleinebudde, P. Solid-state properties and dissolution behaviour of tablets containing co-amorphous indomethacin–arginine. Eur. J. Pharm. Biopharm. 2015, 96, 44–52. [Google Scholar] [CrossRef] [PubMed]
- da Costa, N.F.; Fernandes, A.I.; Pinto, J.F. Measurement of the amorphous fraction of olanzapine incorporated in a co-amorphous formulation. Int. J. Pharm. 2020, 588, 119716. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
da Costa, N.F.; Pinto, J.F.; Fernandes, A.I. Cohesiveness of Powdered Co-Amorphous Olanzapine and Impact on Tablet Production. Med. Sci. Forum 2021, 5, 2. https://doi.org/10.3390/msf2021005002
da Costa NF, Pinto JF, Fernandes AI. Cohesiveness of Powdered Co-Amorphous Olanzapine and Impact on Tablet Production. Medical Sciences Forum. 2021; 5(1):2. https://doi.org/10.3390/msf2021005002
Chicago/Turabian Styleda Costa, Nuno F., João F. Pinto, and Ana I. Fernandes. 2021. "Cohesiveness of Powdered Co-Amorphous Olanzapine and Impact on Tablet Production" Medical Sciences Forum 5, no. 1: 2. https://doi.org/10.3390/msf2021005002
APA Styleda Costa, N. F., Pinto, J. F., & Fernandes, A. I. (2021). Cohesiveness of Powdered Co-Amorphous Olanzapine and Impact on Tablet Production. Medical Sciences Forum, 5(1), 2. https://doi.org/10.3390/msf2021005002